Literature DB >> 15488758

TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.

Antonella Tacconelli1, Antonietta R Farina, Lucia Cappabianca, Giuseppina Desantis, Alessandra Tessitore, Antonella Vetuschi, Roberta Sferra, Nadia Rucci, Beatrice Argenti, Isabella Screpanti, Alberto Gulino, Andrew R Mackay.   

Abstract

We identify a novel alternative TrkA splice variant, TrkAIII, with deletion of exons 6, 7, and 9 and functional extracellular IG-C1 and N-glycosylation domains, that exhibits expression restricted to undifferentiated early neural progenitors, human neuroblastomas (NBs), and a subset of other neural crest-derived tumors. This NGF-unresponsive isoform is oncogenic in NIH3T3 cells and promotes tumorigenic NB cell behavior in vitro and in vivo (cell survival, xenograft growth, angiogenesis) resulting from spontaneous tyrosine kinase activity and IP3K/Akt/NF-kappaB but not Ras/MAPK signaling. TrkAIII antagonizes NGF/TrkAI signaling, which is responsible for NB growth arrest and differentiation through Ras/MAPK, and its expression is promoted by hypoxia at the expense of NGF-responsive receptors, providing a mechanism for converting NGF/TrkA/Ras/MAPK antioncogenic signals to TrkAIII/IP3K/Akt/NF-kappaB tumor-promoting signals during tumor progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488758     DOI: 10.1016/j.ccr.2004.09.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  73 in total

1.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 2.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

3.  Hypoxia regulates alternative splicing of HIF and non-HIF target genes.

Authors:  Johnny A Sena; Liyi Wang; Lynn E Heasley; Cheng-Jun Hu
Journal:  Mol Cancer Res       Date:  2014-05-21       Impact factor: 5.852

4.  Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma.

Authors:  Cong Hua; Gang Zhao; Yan Feng; Hongyan Yuan; Hongmei Song; Li Bie
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

5.  The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.

Authors:  Antonietta Rosella Farina; Antonella Tacconelli; Lucia Cappabianca; Gesilia Cea; Sonia Panella; Antonella Chioda; Alessandra Romanelli; Carlo Pedone; Alberto Gulino; Andrew Reay Mackay
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 6.  On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Authors:  Carol J Thiele; Zhijie Li; Amy E McKee
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

Review 7.  Spontaneous regression of neuroblastoma.

Authors:  Garrett M Brodeur
Journal:  Cell Tissue Res       Date:  2018-01-05       Impact factor: 5.249

Review 8.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

9.  A truncated human NKG2D splice isoform negatively regulates NKG2D-mediated function.

Authors:  Cynthia L Baldwin; Taku Kambayashi; Mobin A Karimi; Oscar Aguilar; Baixiang Zou; Michael H Bachmann; James R Carlyle
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

10.  The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

Authors:  Sophie Beyer; Malene Maag Kristensen; Kim Steen Jensen; Jens Vilstrup Johansen; Peter Staller
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.